| Dermatitis |
| Active, not recruiting | 2b | 210 | Europe, US | Orismilast modified release tablets, Placebo | UNION therapeutics | Atopic Dermatitis, Skin Diseases | 01/24 | 02/24 | | |
| Terminated | 2a | 63 | Europe | Broncho-Vaxom, OM-85, Placebo | OM Pharma SA, OM Pharma | Atopic Dermatitis | 07/23 | 07/23 | | |
RN Immuno-3: NF kappa B decoy oligonucleotide for treatment of atopic dermatitis in Japan |
|
|
| Recruiting | 2 | 0 | RestOfWorld | | AnGes MG, Shionogi | Other Inflammatory Diseases / Healthy Sub. | | | | |
ACTRN12612000837820: The efficacy of topical Alpha ointment (containing natural Henna) on healing of radiation-induced dermatitis in breast cancer patients |
|
|
| Recruiting | 2 | 60 | | | Shiraz University of Medical Sciences, Shiraz University of Medical Sciences | Breast cancer | | | | |
NCT01470872: Neoviderm in the Prevention of Radiation Dermatitis |
|
|
| Recruiting | 2 | 60 | Canada | Aveeno cream and Flamazine cream, Neoviderm cream | Sir Mortimer B. Davis - Jewish General Hospital, Avario Healthcare Inc. | Breast Cancer, Head and Neck Cancer | 12/12 | 12/12 | | |
ChiCTR-TRC-12003174: Effectiveness of PeiTu QingXin (PTQX) Granules adds on usual care to reduce the accumulated relapse of the atopic dermatitis in children: A protocol for a multi-center, double-blind, randomized controlled trial |
|
|
| Completed | 2 | 380 | | the Chinese medicine granules Pei Tu Qing Xin ;Placebo | Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine; Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine of China | Atopic dermatitis | | | | |
2015-000881-73: PRAgmatic trial, Multicentre, cross-over, evaluating in patients with atopic dermatitis the long-term control effectiveness of new phototherapy regimen during winter, in supplement of standard topical treatmements, with oral vitamin D supplementation or not Etude PRAgmatique, multicentrique, en cross-over, évaluant chez des sujets atteints de Dermatite Atopique, l’efficacité sur le contrôle à long terme d’un nouveau protocole de photothérpaie pendant l’hiver, en traitement supplémentaire aux traitements topiques standards, avec ou sans supplémentation en vitamine D |
|
|
| Not yet recruiting | 2 | 200 | Europe | Vitamine D, Oral liquid, UVEDOSE | CHU de Rennes, Projet Hospitalier de Recherche Clinique | Atopic Dermatitis Dermatite atopique, eczema Eczéma, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Not yet recruiting | 2 | 60 | Europe | Ammoniated Mercury, Aluminum chloride hexahydrate, Aluminum lactate, Sodium tetrachloropalladate, Ammoniated Mercury 1.0% w/w in petrolatum, Elemental Mercury 0.5% w/w in petrolatum, Aluminum Chloride Hexahydrate 10.0% w/w in petrolatum, Aluminum Lactate 12.0 % w/w in petrolatum, Sodium tetrachloropalladate 3.0% w/w in petrolatum, Palladium Chloride 1.0% w/w in petrolatum, Panel 1, Panel 2, Panel 3, Reference allergen for Panel 1, Reference Allergen for Panel 1, Reference Allergen for Panel 2, Reference Allergen for Panel 3, Transdermal patch, Cutaneous suspension | SMARTPRACTICE, SmartPractice | Diagnosis of Allergic Contact Dermatitis Diagnosis of Allergic Contact Dermatitis, Skin Rash, Eczema Skin Rash, Eczema, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | | | | |
2004-003734-34: A one-weel, randomized, double-blind, placebo-controlled pilot trial to evaluate oral R129160 (60 mg b.i.d.) on the alleviation of itch in atopic dermatitis patients |
|
|
| Ongoing | 2 | 40 | Europe | R129160, | Barrier Therapeutics nv | Atopic Dermatitis | | | | |
2005-001371-35: A Double-Blind, Placebo Controlled, Half-Head Design, CPO Solution Dose Ranging-Finding Study in Patients with Seborrhoeic Dermatitis of the Scalp |
|
|
| Ongoing | 2 | 60 | Europe | CPO 1.5% Solution, CPO 1.0% Solution, CPO 0.5% Solution, | Stiefel Laboratories Maidenhead Ltd (commonly known as Stiefel Laboratories International Division) | Seborrhoeic dermatitis | | | | |
2006-001564-22: A Phase IIa Multiple-Centre Randomized, Double-Blind, Placebo- Controlled, Parallel Group Study To Investigate The Efficacy Of M5161 In Relieving Pruritus Associated With Atopic Dermatitis. |
|
|
| Ongoing | 2 | 90 | Europe | M5161, | Maruho Co, Ltd. Kyoto R&D Center | | | | | |
2006-005637-37: Comparative, placebo controlled, double-blind efficacy and safety study in patients with seborrhoeic dermatitis comparing a topical cream containing 2% Nicotinamide combined with either 0%, 0.5% or 1.0% GMCY with the placebo cream. |
|
|
| Ongoing | 2 | 100 | Europe | ASF-1057 cream glycerylmonocaprylate 1.0% + nictotinamide 2%, ASF-1057 cream glycerylmonocaprylate 0.5% + nictotinamide 2%, ASF-1057 cream glycerylmonocaprylate 0% + nictotinamide 2%, | Astion Danmark A/S | Seborrhoeic Dermatitis. | | | | |
2007-002550-27: DOUBLE-BLIND, RANDOMISED, ACTIVE AND PLACEBO CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY, SKIN TOLERABILITY AND PHARMACOLOGICAL ACTIVITY OF A NEW TOPICAL COMPOUND (UR-1505 0.5%, 1% AND 2%) IN PATIENTS WITH MILD TO MODERATE ATOPIC DERMATITIS |
|
|
| Ongoing | 2 | 66 | Europe | UR-1505 2% ointment, UR-1505 1% ointment, UR-1505 0.5% ointment, UR-1505, Protopic 0.1% ointment, Protopic 0.1% ointment | Palau Pharma SA | Atopic dermatitis | | | | |
2007-003106-99: Pimecrolimus and Epidermal Barrier Function: Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1% triamcinolone acetonide cream as treatment control twice daily for 3 weeks |
|
|
| Ongoing | 2 | 15 | Europe | elidel 1 % cream, Triamgalen 0.1 % cream, elidel 1 % cream, Triamgalen 0.1 % cream | University of Kiel, Department of Dermatology | Investigative study of pathogenesis/treatment of calcineurin inhibitor vs. corticosteroid confirmatory study to prior study: Pimecrolimus and Epidermal Barrier Function, Protocol No. ELBE-2005, EudraCT No.: 2004-004824-11 | | | | |
2007-007315-93: Human skin blanching essay comparing a new shampoo containing betamethasone dipropionate at 0.025% and 0.050% to three reference marketed formulations in healthy subjects |
|
|
| Ongoing | 2 | 35 | Europe | V0071 GM 01A, Clobex, Diprosone, Localyn glicole, Clobex, Diprosone, Localyn glicole | Pierre Fabre dermatologie | As it\'s a Mc Kensie and Stoughton test, there is no medical condition to be investigated in this trial.The intended indication for the betamethasone dipropionate shampoo is seborrhoeic dermatitis of the scalp in adult. | | | | |
2007-007088-25: Efficacy and tolerance of V0071 GM 01A in inflammatory seborrhoeic dermatitis of the scalp. |
|
|
| Ongoing | 2 | 40 | Europe | V0071 GM 01A, ketoderm 2% (foaming) gel, ketoderm 2% (foaming) gel | Pierre Fabre Dermatologie | Inflammatory seborrhoeic dermatitis of the scalp in adult | | | | |
2007-007789-39: Efficacy and safety comparison of CD4802 0.1% ointment versus vehicle in the treatment of target lesions in adults with atopic dermatitis |
|
|
| Ongoing | 2 | 20 | Europe | CD4802, | GALDERMA R&D SNC | Atopic Dermatitis | | | | |
2008-002284-13: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO ASSESS THE ANTI-INFLAMMATORY PROPERTIES OF TOPICAL CRX-197 IN LESIONAL SKIN OF ADULT SUBJECTS WITH MILD TO MODERATE ATOPIC DERMATITIS |
|
|
| Ongoing | 2 | 60 | Europe | CRx-197 topical cream, 0.1% nortriptyline, | CombinatoRx, Incorporated | mild to moderate atopic dermatitis | | | | |
2008-008353-35: EFFICACY STUDY OF A CICLOPIROXOLAMINE 1% FOAM (DC115 GM 02A) VERSUS CICLOPIROXOLAMINE 1.5% SHAMPOO (SEBIPROX®) IN THE TREATMENT OF MODERATE SEBORRHEIC DERMATITIS OF THE SCALP |
|
|
| Ongoing | 2 | 44 | Europe | SEBIPROX, DC115GM02A, SEBIPROX, SEBIPROX | PIERRE FABRE DERMATOLOGIE REPRESENTED BY INSTITUT DE RECHERCHE PIERRE FABRE | Topical treatment of moderate seborrheic dermatitis of the scalp | | | | |
| Ongoing | 2 | 20 | Europe | Hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyral®), | SmartPractice, SmartPractice | Diagnosis of Allergic Contact Dermatitis | | | | |
| Ongoing | 2 | 54 | Europe | NIAD Gel, | Dermal Laboratories Limited | The medical condition to be investigated in this study is atopic eczema, also known as atopic dermatitis. | | | | |
2016-002539-14: A study to investigate the effect of ANB020 or placebo in patients with moderate to severe Atopic Dermatitis when exposed to House Dust Mites. |
|
|
| Ongoing | 2 | 12 | Europe | ANB020, Solution for infusion | AnaptysBio Inc, AnaptysBio Inc. | Atopic dermatitis, Atopic dermatitis is a form of eczema. It is a condition that causes the skin to become itchy, red, dry and cracked. It can affect any part of the body., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
Vanda, NCT02672410: Tradipitant in Treatment-Resistant Pruritus Associated With Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 7 | US | Tradipitant, Placebo | Sadick Research Group | Atopic Dermatitis | 12/17 | | | |
ChiCTR-IIR-17012153: Multi-centre, randomised, double-blind, placebo- and comparator-controlled trial on benvitimod cream in patients with Atopic Dermatitis |
|
|
| Recruiting | 2 | 120 | | 0.5% Benvitimod cream ;1.0% Benvitimod cream ;Placebo ;Tacrolimus | Peking University People's Hospital; Beijing Wenfeng Tianji Pharmaceuticals Co., Ltd., Beijing Wenfeng Tianji Pharmaceuticals Co.,Ltd. | Atopic Dermatitis | | | | |
| Ongoing | 2 | 36 | Europe | Omiganan Topical Gel, Nizoral 20 mg/g, crème, CLS001, Nizoral 20 mg/g, crème, Gel, Cream, Nizoral 20 mg/g, crème | Cutanea Life Sciences, Cutanea Life Sciences | Mild to moderate facial seborrheic dermatitis., facial seborrheic dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
KSSI, ChiCTR2100049164: Compound Kushen injection alleviates radiation-induced skin injury: randomized controlled trial |
|
|
| Completed | 2 | 60 | | Compound Kushen injection was given intravenously every day during radiotherapy ;Radiotherapy | Department of radiotherapy, Guangdong Provincial Hospital of traditional Chinese Medicine; Guangdong Provincial Hospital of traditional Chinese Medicine, self financing | acute radiation dermatitis | | | | |
2019-002771-33: A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults with Mild to Moderate Atopic Dermatitis |
|
|
| Ongoing | 2 | 226 | Europe, RoW | ATx201 OINTMENT, ATx201, Ointment | UNION therapeutics A/S, UNION therapeutics A/S | Atopic Dermatitis, Eczema, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
ChiCTR1800018939: Clinical study for the effect of Lian-Bai paste in the protection and treatment of acute radiodermatitis |
|
|
| Recruiting | 2 | 154 | | Lianbai Paste ;Danru | the Second Affiliated Hospital of Xi'an Jiaotong University; the Second Affiliated Hospital of Xi'an Jiaotong University, Projects of traditional Chinese medicine of Shaanxi Administration of Traditional Chinese Medicine | acute radiodermatitis | | | | |
2018-003429-27: A Study to Assess the Efficacy and Safety of MSTT1041A in Patients with Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 90 | Europe | MSTT1041A, Ro 718-7807/F01-01, Solution for injection | Genentech Inc., Genentech Inc. c/o F. Hoffmann-La Roche Ltd | Moderate to severe atopic dermatitis, Atopic dermatitis (AD), is a type of inflammation of the skin (dermatitis) that results in itchy, red, swollen, and cracked skin, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Not yet recruiting | 2 | 37 | Europe | Eucrisa, Betnovate Cream, Crisaborole PF-06930164, 10949/0014, Ointment, Cream, Eucrisa, Betnovate Cream | Sheffield Teaching Hospitals NHS Foundation Trust, Pfizer Inc. | atopic eczema (synonym atopic dermatitis) and the adverse treatment side effect epidermal atrophy, atopic eczema (synonym atopic dermatitis) is a chronic, relapsing, inflammatory disease of the skin. Epidermal atrophy is skin thinning, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2019-000932-25: Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients with Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 220 | Europe | DS107 Capsule, DS107G, Capsule, soft | DS Biopharma Ltd., DS Biopharma Ltd. | Moderate to Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2018-000998-72: A clinical study to test the safety and possible benefits of an investigational study drug, KHK4083, in patients with atopic dermatitis. |
|
|
| Not yet recruiting | 2 | 250 | Europe | KHK4083, KHK4083, Solution for injection | Kyowa Kirin Co., Ltd., Kyowa Kirin Co., Ltd | Moderate to Severe Atopic Dermatitis, Moderate to severe eczema, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
ChiCTR2000037991: A randomized, double-blind, dose-exploration, multi-center phase II clinical trial for the efficacy and safety of Peitu Qingxin (PTQX) Granules in the treatment of atopic dermatitis in children (heart fire and spleen deficiency syndrome) |
|
|
| Recruiting | 2 | 120 | | High-dose PeiTu QingXin (PTQX) Granules ;Low-dose PeiTu QingXin (PTQX) Granules ;Very low-dose PeiTu QingXin (PTQX) Granules | The First Teaching Hospital of Tianjin University of TCM; YOUCARE PHARMACEUTICAL GROUP CO., LTD., YOUCARE PHARMACEUTICAL GROUP CO.,LTD. | Atopic dermatitis | | | | |
2018-000783-29: A Study of GBR 830 in Adult Patients with Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 468 | Europe | ISB 830, Powder for solution for infusion | Ichnos Sciences SA, Inchos Sciences SA (renamed from Glenmark Pharmaceuticals SA), Ichnos Sciences SA, Inchos Sciences SA | Moderate to severe atopic dermatitis, Moderate to severe eczema, Diseases [C] - Immune System Diseases [C20] | | | | |
2020-003977-23: A study of the efficacy, safety, tolerability and pharmacokinetics of PF07038124 ointment in participants with eczema or psoriasis |
|
|
| Not yet recruiting | 2 | 88 | Europe | PF-07038124, Ointment | Pfizer Inc., Pfizer Inc. | Mild to moderate atopic dermatitis or mild to moderate plaque psoriasis, Eczema or psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-000448-23: A Multicenter trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects with Moderate-to-Severe Atopic Dermatitis |
|
|
| Ongoing | 2 | 70 | Europe | Nemolizumab, CD14152, Powder and solution for solution for injection | Galderma S.A., Galderma S.A. | Moderate-to-Severe Atopic Dermatitis, Moderate-to-Severe Atopic Dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Not yet recruiting | 2 | 24 | Europe | Anti-interleukin-36 receptor (IL-36R) monoclonal antibody, ANB019, Solution for injection | AnaptysBio Inc., AnaptysBio Inc. | Ichthyosis Rybia łuska, The ichthyoses are a group of rare chronic genetic disorders that share characteristics of scaling and underlying skin inflammation to varying degrees, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT03614221: Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis |
|
|
| Completed | 2 | 22 | RoW | Lindioil ointment, Indigo naturalis oil extract ointment, Protopic ointment 0.1%, Tacrolimus ointment 0.1% | Chang Gung Memorial Hospital, Ministry of Science and Technology, Taiwan | Atopic Dermatitis | 12/21 | 12/21 | | |
NCT04413942: Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 99 | US | FB825, Placebo | Oneness Biotech Co., Ltd. | Atopic Dermatitis | 12/21 | 06/22 | | |
2021-000725-28: A Subcutaneous Dose Ranging Study of KY1005 in Patients with Moderate to Severe Atopic Dermatitis Búsqueda de dosis subcutáneo de KY1005 en pacientes con dermatitis atópica moderada o grave |
|
|
| Not yet recruiting | 2 | 350 | Europe, RoW | KY1005, SAR445229, Solution for injection | Kymab Limited, Kymab Ltd, a Sanofi Company, Kymab Limited | Atopic dermatitis dermatitis atópica, Eczema Eczema, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2020-005900-21: A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV doses of Bermekimab for the Treatment of Adult Participants with Moderate-to-Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 60 | Europe | bermekimab, JNJ-77474462, Solution for infusion in pre-filled syringe | Janssen-Cilag International NV, Janssen Research & Development, LLC | Moderate to Severe Atopic Dermatitis, Moderate to Severe Eczema, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2020-002587-31: A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants with Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 200 | Europe | bermekimab, Dupixent®, JNJ-77474462, Solution for injection in pre-filled syringe, Dupixent® | Janssen-Cilag International NV, Janssen Research & Development, LLC | Moderate to Severe Atopic Dermatitis, Moderate to Severe Eczema, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT04539639: Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis |
|
|
| Completed | 2 | 166 | RoW | Jaktinib, placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Atopic Dermatitis | 05/22 | 05/22 | | |
2019-000598-22: Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki) Die Auswirkung einer Tralokinumab-Behandlung auf die Hautbarrierefunktion bei Patienten mit moderater bis schwerer Neurodermitis (TraSki) |
|
|
| Not yet recruiting | 2 | 16 | Europe | Tralokinumab, Solution for injection in pre-filled syringe, Adtralza | University Hospital Schleswig Holstein, Represented by the Board of Directors which is represented by the chairman, LEO Pharma A/S | Patients with moderate to severe atopic dermatitis Patienten mit moderater bis schwerer Neurodermitis, Patients with moderate to severe atopic dermatitis Patienten mit moderater bis schwerer Neurodermitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
TraSki, NCT04556461: Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function |
|
|
| Completed | 2 | 16 | Europe | Tralokinumab | Prof. Dr. Stephan Weidinger | Atopic Dermatitis | 07/22 | 03/23 | | |
2021-002344-73: Long-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis. Az amlitelimab hosszú távú biztonságosságának és hatásosságának értékelése mérsékelt vagy súlyos atópiás dermatitiszben szenvedő felnőtt résztvevőknél |
|
|
| Ongoing | 2 | 315 | Europe, RoW | Amlitelimab, SAR445229, Solution for injection | Sanofi-aventis recherche & développement, Sanofi-aventis recherche & développement | Dermatitis atopic Atópiás dermatitisz, Immune system diseases Immunrendszer megbetegedése, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04888234: Evaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis. |
|
|
| Not yet recruiting | 2 | 30 | NA | Ru-Yi-Jin-Huang Powder | Chang Gung Memorial Hospital | Radiation Dermatitis | 07/22 | 07/22 | | |
NCT05014438: A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis |
|
|
| Completed | 2 | 17 | Europe, Canada, US, RoW | BMS-986166, Branebrutinib, BMS-986195, Placebo | Bristol-Myers Squibb | Dermatitis, Atopic | 08/22 | 08/22 | | |
2020-004767-77: A Phase 2, Double-blind, placebo-controlled study of BMS-986166 or Branebrutinib in Patients with Moderate to Severe Atopic Dermatitis. Estudio fase 2, doble ciego y controlado con placebo de BMS-986166 o branebrutinib en pacientes con dermatitis atópica de moderada a grave |
|
|
| Not yet recruiting | 2 | 240 | Europe | S1P Receptor Modulator, Branebrutinib, BMS-986166, BMS-986195, Capsule, hard | Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation | Moderate to Severe Atopic Dermatitis. Dermatitis atópica de moderada a grave, Atopic dermatitis is a chronic condition characterized by red, itchy, dry, bumpy patches of skin. Lesions are typically found in the hands, neck, upper chest, inner elbows, and backs of the knees. DA: enfermedad crónica con zonas de piel enrojecida,con picor,descamación,hinchazón. Las lesiones aparecen en manos,cuello, parte superior del pecho,cara interna de codos,parte posterior de rodillas, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05079763: Bacterial Cellulose-monolaurin Hydrogel for Acute Radiation Dermatitis |
|
|
| Recruiting | 2 | 54 | RoW | Bacterial cellulose-monolaurin hydrogel, Placebo cream | University of the Philippines | Acute Radiation Dermatitis | 09/22 | 12/22 | | |
2020-005541-16: An evaluation of LEO 138559 in adults with moderate to severe atopic dermatitis |
|
|
| Not yet recruiting | 2 | 52 | Europe | LEO 138559 lyophilisate, for solution for injection (150 mg/mL), LEO 138559, Lyophilisate for solution for injection | LEO Pharma A/S, LEO Pharma A/S | Atopic Dermatitis (AD), Eczema, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT04306965: Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab |
|
|
| Completed | 2 | 10 | US | Apremilast, Otezla | Tufts Medical Center, Amgen | Atopic Dermatitis | 06/22 | 08/22 | | |
2020-005212-22: The purpose of this study is to see if CC-93538 is safe and effective as a possible treatment for moderate to severe Atopic Dermatitis. Multicentrické globální, randomizované, dvojitě zaslepené, placebem kontrolované klinické hodnocení fáze 2 s paralelními skupinami hodnotící bezpečnost a snášenlivost cendakimabu (CC-93538) u dospělých pacientů se středně těžkou až těžkou atopickou dermatitidou |
|
|
| Not yet recruiting | 2 | 200 | RoW | Cendakimab, CC-93538, Solution for injection/infusion in pre-filled syringe | Celgene International II Sàrl, Celgene Corporation | ATOPIC DERMATITIS, Atopic dermatitis (AD) is a common and chronic inflammatory skin disorder that affects a broad demographic, with an increasing prevalence worldwide., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2022-001625-79: A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 130 | Europe | lirentelimab, AK002, Solution for injection | Allakos Inc., Allakos Inc. | Atopic Dermatitis, Atopic Eczema, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT03680131: Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis |
|
|
| Active, not recruiting | 2 | 126 | Canada, US | EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0% | Edesa Biotech Inc., JSS Medical Research Inc. | Allergic Contact Dermatitis | 12/22 | 03/23 | | |
NCT05017480: A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China |
|
|
| Completed | 2 | 330 | RoW | CBP-201, Placebo | Suzhou Connect Biopharmaceuticals, Ltd. | Moderate-to-severe Atopic Dermatitis | 12/22 | 09/23 | | |
|
2020-003406-31: A study to assess if CMK389 is effective, safe and tolerable in patients with moderate to severe Atopic Dermatitis (AD) |
|
|
| Not yet recruiting | 2 | 64 | Europe, RoW | CMK389, Powder for solution for injection/infusion | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Moderate to Severe Atopic Dermatitis, Atopic dermatitis / eczema, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2022-000520-38: A study to learn how well the study treatment zabedosertib (BAY1834845) works and how safe it is compared to placebo in adult participants with moderate-to-severe atopic dermatitis Studie s cílem zjistit, jak dobře studovaná léčba zabedosertibem (BAY1834845) funguje a jak je bezpečná v porovnání s placebem u dospělých pacientů se středně těžkou až těžkou atopickou dermatitidou |
|
|
| Ongoing | 2 | 72 | RoW, Europe | BAY 1834845 coated tablet 120 mg, BAY 1834845 coated tablet 120 mg 123, Coated tablet | Bayer AG, Bayer AG | Atopic dermatitis, Long lasting inflammation of the skin, also called eczema, causing patches of skin to become swollen, red, cracked, and itchy, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT04137562: Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 118 | RoW | ADSTEM Inj., Placebo | EHL Bio Co., Ltd. | Atopic Dermatitis | 01/23 | 10/27 | | |
| Active, not recruiting | 2 | 104 | RoW | ZAX.1400.P03, Placebo | Fasa University of Medical Sciences, Zarrin Avaye Kowsar Salamat (ZAX company) | Psoriasis, Inflammation, Skin Diseases | 03/24 | 12/24 | | |
2022-001528-14: A Study of JNJ-67484703 in the Treatment of Participants with Moderate to Severe Atopic Dermatitis |
|
|
| Ongoing | 2 | 51 | Europe | JNJ-67484703, Solution for injection | Janssen-Cilag International NV, Janssen Research & Development, LLC | Atopic Dermatitis, An itchy inflammation of the skin, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
PRADA, NCT02537509: PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter Coupled With Oral Vitamin D Supplementation vs. Placebo |
|
|
| Completed | 2 | 111 | Europe | Cholecalciferol, Uvedose, Placebo of cholecalciferol, Placebo of Uvedose | Rennes University Hospital | Atopic Dermatitis | 03/23 | 03/23 | | |
| Completed | 2 | 421 | Europe, Canada, US, RoW | EDP1815, Prevotella histicola, Placebo | Evelo Biosciences, Inc. | Atopic Dermatitis | 03/23 | 03/23 | | |
STREAM-AD, NCT05131477: Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The Study |
|
|
| Completed | 2 | 390 | Europe, Canada, Japan, US, RoW | KY1005, Amlitelimab, SAR445229, A human anti-OX40 ligand monoclonal antibody, Placebo | Kymab Limited, Sanofi | Eczema, Atopic Dermatitis | 04/23 | 02/24 | | |
ACTRN12622000395730: Study of topical AB-101 hydrogel versus vehicle in participants with atopic dermatitis. |
|
|
| Completed | 2 | 72 | | | Alphyn Biologics Australia Pty. Ltd., a subsidiary of Alphyn Biologics, LLC, Alphyn Biologics Australia Pty. Ltd., a subsidiary of Alphyn Biologics, LLC | Atopic Dermatitis | | | | |
| Terminated | 2 | 287 | Europe, Canada, US, RoW | EDP1815, Prevotella histicola | Evelo Biosciences, Inc. | Atopic Dermatitis | 05/23 | 06/23 | | |
NCT04893707: The Study of CM310 in Patients With Atopic Dermatitis |
|
|
| Recruiting | 2 | 459 | RoW | CM310, IL-4Rα monoclonal antibody | Keymed Biosciences Co.Ltd | Moderate-to-severe Atopic Dermatitis | 06/23 | 06/23 | | |
2020-000229-24: An Open-label Drug-Drug Interaction Study to Assess the Effects ofNemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Serve Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 25 | Europe | Nemolizumab, CD14152, Powder and solution for solution for injection, Solution for injection, Tablet, Midazolam Injection, USP, MsKesson Omeprazole Delayed Release Tablets 20 mg, WARFARIN SODIUM – warfarin sodium tablet, JET-ALERT Regular Strength, Metoprolol Tartrate Tablets, USP | Galderma S.A., Galderma S.A. | Moderate-to-severe atopic dermatitis, Atopic dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2020-004382-39: This is an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active polymyositis or dermatomyositis who completed the double-blind treatment period of Study KZR-616-003 (EudraCT Number: 2019-002605-22), up to and including the Week 32 Visit, prior to the first dose of open-label KZR-616. |
|
|
| Not yet recruiting | 2 | 24 | RoW | KZR-616, Lyophilisate for solution for injection | Kezar Life Sciences, Inc., Kezar life Sciences, Inc. | Autoimmune Disorders Polymyositis and Dermatomyositis, inflammation of the muscles; inflammation of the skin, Diseases [C] - Immune System Diseases [C20] | | | | |
| Completed | 2 | 302 | Europe, Canada, US, RoW | Placebo Comparator, ASLAN004 | ASLAN Pharmaceuticals | Atopic Dermatitis | 06/23 | 09/23 | | |
NCT06085521: A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 2 | 150 | RoW | LNK01001 Dose A, LNK01001 Dose B, placebo | Lynk Pharmaceuticals Co., Ltd | Atopic Dermatitis | 06/23 | 06/23 | | |
| Completed | 2 | 124 | Europe, Canada, US, RoW | Placebo, Rilzabrutinib, PRN1008/SAR444671 | Sanofi | Atopic Dermatitis | 06/23 | 06/23 | | |
NCT05470114: A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD |
|
|
| Completed | 2 | 13 | Europe | LEO 138559, Dupixent® | LEO Pharma | Atopic Dermatitis | 06/23 | 10/23 | | |
| Completed | 2 | 93 | RoW | 611 Q2W, 611 Q4W, Matching placebo, placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 07/23 | 09/23 | | |
NCT04365387: A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab |
|
|
| Completed | 2 | 225 | US | Nemolizumab, Placebo | Galderma R&D | Dermatitis, Atopic | 07/23 | 07/23 | | |
NCT04562116: A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Completed | 2 | 16 | Europe, US | Nemolizumab, CD14152, CYP 450 Substrates | Galderma R&D | Atopic Dermatitis | 06/23 | 06/23 | | |
| Completed | 2 | 216 | Europe, Canada, Japan, US, RoW | LEO 152020 tablet, LEO 152020 placebo tablet | JW Pharmaceutical, LEO Pharma | Atopic Dermatitis | 07/23 | 07/23 | | |
NCT05579899: Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis |
|
|
| Completed | 2 | 119 | US | EVO101 | Evommune, Inc. | Atopic Dermatitis Eczema | 07/23 | 07/23 | | |
NCT05769946: A Study of Hemay005 in Adult With Atopic Dermatitis |
|
|
| Completed | 2 | 79 | RoW | Hemay005 | Ganzhou Hemay Pharmaceutical Co., Ltd | Hemay005, Atopic Dermatitis | 01/24 | 02/24 | | |
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 75 | RoW | ICP-332, ICP-332 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Atopic Dermatitis | 07/23 | 12/23 | | |
NCT05375955: A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. |
|
|
| Completed | 2 | 264 | Europe, Canada, Japan, US | PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06% | Pfizer | Atopic Dermatitis, Plaque Psoriasis | 07/23 | 07/23 | | |
NCT05127421: Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement |
|
|
| Completed | 2 | 77 | US | Ruxolitinib cream, Vehicle | Incyte Corporation | Atopic Dermatitis | 08/23 | 09/23 | | |
NCT04149522: Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer |
|
|
| Terminated | 2 | 40 | US | Mepitel Film® | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Breast Cancer, Radiotherapy; Adverse Effect, Dermatitis or Eczema, Radiotherapy Side Effect, Radiation Burn, Radiation Dermatitis, Radiotherapy; Complications | 08/23 | 11/23 | | |
NCT05549947: Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis |
|
|
| Completed | 2 | 158 | RoW | SHR1819, Placebo | Shanghai Hengrui Pharmaceutical Co., Ltd. | Moderate to Severe Atopic Dermatitis | 09/23 | 11/23 | | |
NCT05466877: A Study of MG-K10 in Subjects With Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 163 | RoW | MG-K10, Placebo | Shanghai Mabgeek Biotech.Co.Ltd | Atopic Dermatitis | 09/23 | 05/24 | | |
REZOLVE-AD, NCT06136741: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 396 | Europe, Canada, US, RoW | Rezpegaldesleukin, NKTR-358, REZPEG, LY3471851 (formerly), Placebo | Nektar Therapeutics | Moderate to Severe Atopic Dermatitis | 05/25 | 12/25 | | |
EASE, NCT06144424: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 30 | Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Atopic Dermatitis | 09/24 | 10/24 | | |
NCT05432596: Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis |
|
|
| Completed | 2 | 250 | US | ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle | Aclaris Therapeutics, Inc. | Atopic Dermatitis | 10/23 | 11/23 | | |
2021-004750-39: Treatment with anakinra versus placebo to patients with nickle allergy |
|
|
| Not yet recruiting | 2 | 22 | Europe | Solution for injection in pre-filled syringe, Kineret | Herlev Gentofte Hospital - Department of Dermatology and Allergy, Leo Foundation | Allergic contact dermatitis. Patients with nickel allergy to be specific, Nickel allergy, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT05048056: Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 105 | US, RoW | Placebo, AK120 | Akesobio Australia Pty Ltd | Atopic Dermatitis | 10/23 | 01/24 | | |
NCT05579925: A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis |
|
|
| Recruiting | 2 | 24 | RoW | CM310 | Keymed Biosciences Co.Ltd | Atopic Dermatitis | 10/23 | 10/23 | | |
| Terminated | 2 | 131 | Europe, US | AK002, Lirentelimab, Placebo | Allakos Inc. | Atopic Dermatitis | 12/23 | 04/24 | | |
| Completed | 2 | 45 | US | Ruxolitinib 1.5% Cream | Icahn School of Medicine at Mount Sinai, Incyte Corporation | Seborrheic Dermatitis | 01/24 | 01/24 | | |
NCT05693597: Evaluation of the Effect of Nigella Sativa for the Prophylaxis to Radiation Induced Dermatitis in Breast Cancer Patients |
|
|
| Completed | 2 | 132 | RoW | Imtenan Oil, Baraka Capsules | German University in Cairo, Ain Shams University | Radiation Dermatitis | 02/24 | 02/24 | | |
NCT06158490: A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis |
|
|
| Not yet recruiting | 2 | 120 | NA | JYP0061 tablet Dose1, JYP0061 tablet Dose1 for 12 weeks, JYP0061 tablet Dose2, JYP0061 tablet Dose2 for 12 weeks, JYP0061 Placebo, JYP0061 Placebo for 12 weeks | Guangzhou JOYO Pharma Co., Ltd, Chengdu JOYO pharma Co., Ltd. | Moderate-to-severe Atopic Dermatitis | 02/25 | 02/25 | | |
NCT05694884: Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab |
|
|
| Recruiting | 2 | 75 | Canada, US | Placebo, ASLAN004 | ASLAN Pharmaceuticals | Atopic Dermatitis | 12/24 | 02/25 | | |
Damask, NCT05656911 / 2022-000520-38: A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis |
|
|
| Completed | 2 | 77 | Europe, US, RoW | Zabedosertib (BAY1834845), Placebo to zabedosertib (BAY 1834845) | Bayer, Bayer AG | Atopic Dermatitis | 01/24 | 01/24 | | |
NCT05671432: The Study of CM326 in Moderate-to-severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 240 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Moderate-to-severe Atopic Dermatitis | 12/23 | 12/24 | | |
| Recruiting | 2 | 130 | US | Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline, Sodium hypochlorite, Placebo capsules, Placebo Sodium hypochlorite | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic, Skin Diseases | 01/25 | 01/25 | | |
NCT04479514: Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy |
|
|
| Active, not recruiting | 2 | 20 | US | Warm Baths or Showers, Moisturizer, SPF 30 or Higher Suncreen, i.e. Neutrogena, Aveeno, Cerave, Blue Lizard, Sun Protective Clothing, Limited Sun Exposure, Dilute bleach baths | Dana-Farber Cancer Institute | Pediatric Cancer, CNS Tumor, Childhood, Skin Inflammation | 01/24 | 12/24 | | |
